GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (NSE:LYKALABS) » Definitions » 12-1 Month Momentum %

Lyka Labs (NSE:LYKALABS) 12-1 Month Momentum % : 18.68% (As of Dec. 13, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lyka Labs 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-13), Lyka Labs's 12-1 Month Momentum % is 18.68%.

The industry rank for Lyka Labs's 12-1 Month Momentum % or its related term are showing as below:

NSE:LYKALABS's 12-1 Month Momentum % is ranked better than
70.38% of 1445 companies
in the Biotechnology industry
Industry Median: -13.2 vs NSE:LYKALABS: 18.68

Competitive Comparison of Lyka Labs's 12-1 Month Momentum %

For the Biotechnology subindustry, Lyka Labs's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Lyka Labs's 12-1 Month Momentum % falls into.



Lyka Labs  (NSE:LYKALABS) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyka Labs  (NSE:LYKALABS) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Lyka Labs 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Lyka Labs's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs Headlines

No Headlines